FDA Grants Accelerated Review For Pfizer Cancer Drug – Wall Street Journal

by lowes1 on May 17, 2011

FDA Grants Accelerated Review For Pfizer Cancer Drug
Wall Street Journal
The fusion of ALK with another gene is believed to be present in about 3% to 5% of people with non-small cell lung cancer, or 40000 patients diagnosed annually worldwide. Mace Rothenberg, senior vice president of clinical development & medical affairs
Pfizer Files NDA For Lung Cancer Drug Crizotinib With FDA, Japan – UpdateRTT News
Pfizer cancer drug takes big step toward fateful FDA decisionFierceBiotech
Pfizer Breaks Barriers with New Lung Cancer DrugFox Business
Forbes -OzarksFirst.com -Xconomy
all 42 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: